GRM5 and Dyskinesia: Nevertheless, in a recent clinical trial of levodopa-induced dyskinesias, the mGlu5 inhibitor AFQ056 (mavoglurant) exhibited antiparkinsonian effects greater than L-Dopa alone on two individual study days [40].